Ipca Laboratories declares Q4FY22 result: Standalone Net total Income up 11% at Rs. 1182.66 crores. Consolidated Net total Income up 15% at Rs.1303.64 crores. Indian formulations income up 27% at Rs. 551.80 crores. Exports Income down 4% at Rs. 527.34 crores. Standalone EBITDA margin (before forex (gain)/loss) @ 16.43% in Q4 FY22 as against @21.08% in Q4 FY21. Consolidated EBITDA margin @ 18.11% in Q4 FY22 as against @ 20.76% in Q4 FY21. Standalone Net Profit at Rs. 110.41 crores down 27%. Consolidated Net Profit at Rs. 130.23 crores down 19%. Result PDF
Conference Call with Ipca Laboratories Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.